Oncology Learning Network
Verified
Online/Digital
Oncology Learning Network® is an online resource for the latest developments in oncology practice, providing a customized experience for readers to stay informed about the topics that matter most to them. Through clinical insights, peer-reviewed journal articles, interactive features, research news updates, accredited continuing educational programs, and professional live meetings and events, Oncology Learning Network serves as a collaborative learning and networking environment for a multidisciplinary community of oncology medical professionals.
As the digital home to the respected and well-known online and live continuing education programs in oncology provided by Imedex and NACCME, Oncology Learning Network allows busy oncology providers to meet all of their educational and informational needs in one place. Source
Actions
Media Outlet details
| Scope | International, Trade/B2B |
|---|---|
| Language | English |
| Country | United States of America |
Similarweb UVM
|
Request pricing |
Comscore UVM
|
Request pricing |
Recent Articles
Search ArticlesFDA Approves Imlunestrant Plus Abemaciclib for ESR1-Mutated Advanced Breast Cancer
Clinical Summary: Regulatory Update: The FDA approved imlunestrant in combination with abemaciclib for adults with ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer whose disease progressed following at least 1 line of endocrine therapy.
Targeting BRAF V600E in Pediatric Cervicomedullary Ganglioglioma
Diana Osorio, MD, MPH, reviews the management of pediatric cervicomedullary ganglioglioma, emphasizing the challenges of treating tumors in a surgically inaccessible location and the importance of early biopsy and molecular profiling. She discusses the clinical and prognostic significance of BRAF V600E and the rationale for BRAF/MEK inhibition with dabrafenib and trametinib.
FDA Approves Taletrectinib Label Update With Longer-Term Response Data in ROS1-Positive Non-Small Cell Lung Cancer
Clinical Summary: Design/Population: The TRUST clinical program evaluated taletrectinib in adults with advanced ROS1-positive NSCLC, including TKI-naive and previously treated patients across the pivotal TRUST-I and TRUST-II studies. Key Outcomes: The updated FDA label includes longer-term TRUST-I data showing a median duration of response of 49.7 months in TKI-naive patients, with continued responses observed in some patients for multiple years.
Low-Dose Ruxolitinib Significantly Reduces Acute Graft-Versus-Host Disease After Haploidentical Transplantation
Clinical Summary: Design/Population: This multicenter, open-label trial compared low-dose ruxolitinib with mycophenolate mofetil as part of an antithymocyte globulin, calcineurin inhibitor, and short-course methotrexate prophylaxis regimen in patients undergoing first myeloablative haploidentical hematopoietic stem-cell transplantation. Key Outcomes: Ruxolitinib-based prophylaxis significantly reduced grade II to IV acute graft-versus-host disease by day 100 compared with standard prophylaxis.
Epcoritamab Plus Lenalidomide and Rituximab Shows Superior Efficacy in Second-Line or Later Follicular Lymphoma
Clinical Summary: Design/Population: The phase 3 EPCORE FL-1 trial randomized patients with CD20-posiive follicular lymphoma who received prior systemic therapy to receive fixed-duration epcoritamab plus lenalidomide and rituximab or lenalidomide plus rituximab alone. Dual primary end points were objective response and progression-free survival (PFS).
Sacituzumab Govitecan Plus Pembrolizumab Fails to Significantly Improve PFS in PD-L1–High Metastatic Non-Small Cell Lung Cancer
Clinical Summary: Design/Population: The phase 3 EVOKE-03 trial compared first-line sacituzumab govitecan plus pembrolizumab with pembrolizumab alone in patients with untreated metastatic non-small cell lung cancer (NSCLC) with PD-L1 tumor proportion score of at least 50% and no EGFR, ALK, or ROS1 alterations.
MRI Surveillance Improves Cognitive Outcomes Compared With Prophylactic Cranial Irradiation in Small Cell Lung Cancer
Clinical Summary: Design/Population: This international phase 3 trial randomized patients with limited- or extensive-stage small cell lung cancer without brain metastases following initial therapy to MRI surveillance alone or MRI surveillance plus prophylactic cranial irradiation. The primary end point was cognitive failure-free survival, with overall survival (OS) noninferiority evaluated as a key secondary end point.
FDA Label Update Shortens Initial Tarlatamab Monitoring to Support Broader Extensive-Stage Small Cell Lung Cancer Treatment Access
Clinical Summary: Regulatory Update: The FDA approved revised prescribing information for tarlatamab that reduces healthcare-setting monitoring following the first 2 infusions from extended overnight observation to 6 to 8 hours, with follow-up assessments the next day.
Sustained Ropeginterferon Alfa-2b Treatment Deepens Molecular Responses in High-Risk Essential Thrombocythemia
Clinical Summary: Design/Population: This extended analysis of the phase 3 SURPASS-ET trial evaluated patients with high-risk essential thrombocythemia and leukocytosis after hydroxyurea failure. Patients initially received ropeginterferon alfa-2b or anagrelide, with eligible patients assigned to anagrelide able to crossover to ropeginterferon alfa-2b after the first year. Key Outcomes: Ropeginterferon alfa-2b produced sustained modified European LeukemiaNet responses through 2 years.
Ropeginterferon Alfa-2b Achieves Increasing Complete Hematologic Response Rates With Longer Treatment in Patients With Myeloproliferative Neoplasms
Clinical Summary: Design/Population: This retrospective study evaluated real-world treatment patterns, tolerability, and complete hematologic responses among patients prescribed ropeginterferon alfa-2b for myeloproliferative neoplasms, primarily polycythemia vera, with additional off-label use in essential thrombocythemia and unclassified myeloproliferative neoplasms.